Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01088321

IM101-045A

Details and patient eligibility

About

The purpose of this study is to compare the incidence rates of infection among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications

Enrollment: 81,332 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of rheumatoid arthritis
• Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM
• Age 18 years or older at the time of drug initiation
• Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation

Exclusion criteria

• Below 18 years of age at the time of BDM or DMARD initiation
• Lacking six months of continuous enrollment prior to the initiation of one of the study drugs

Trial design

81,332 participants in 3 patient groups

Patients initiating abatacept

Patients initiating other biologic disease-modifying drugs

Pts initiate non-biologic disease-modify anti-rheumatic drugs